HSA
NAGE

Hussman Strategic Advisors’s Niagen Bioscience NAGE Stock Holding History

Hussman Strategic Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,000
Closed -$668K – 349
2025
Q4 		$668K Hold
105,000
– – 0.16% 214
2025
Q3 		$980K Buy
+105,000
New +$1.06M 0.21% 201
2022
Q2 		– Sell
-52,000
Closed -$128K – 367
2022
Q1 		$128K Hold
52,000
– – 0.02% 301
2021
Q4 		$194K Buy
+52,000
New +$281K 0.04% 298

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hussman Strategic Advisors's NAGE Position: Q1 2026 in Review

Hussman Strategic Advisors sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 105,000 shares — an estimated $668K sold.

Hussman Strategic Advisors first reported a position in NAGE in Q4 2021 and held it in 4 quarters. The position peaked at $980K in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Hussman Strategic Advisors reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 105,000 Niagen Bioscience shares in Q1 2026, an estimated $668K.
  • Hussman Strategic Advisors first reported a position in Niagen Bioscience in Q4 2021 and held it in 4 quarters.
  • Hussman Strategic Advisors's Niagen Bioscience position peaked at $980K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.